ProQR (PRQR)
1.79
-0.02 (1.10%)
Upcoming Events
Latest Headlines
Form 4 ProQR Therapeutics N.V. For: Jul 17 Filed by: Filius Bart
July 21, 2026 8:00 AM - SEC Filing
Form EFFECT ProQR Therapeutics N.V.
July 16, 2026 6:05 AM - SEC Filing
Form 424B5 ProQR Therapeutics N.V.
July 15, 2026 4:30 PM - SEC Filing
Form SCHEDULE 13G/A ProQR Therapeutics N.V. Filed by: Privium Fund Management B.V.
July 15, 2026 11:55 AM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jul 09 Filed by: de Boer Daniel Anton
July 13, 2026 8:00 AM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jul 07 Filed by: de Boer Daniel Anton
July 8, 2026 2:55 PM - SEC Filing
Form F-3 ProQR Therapeutics N.V.
July 6, 2026 4:11 PM - SEC Filing
Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.
June 30, 2026 5:23 PM - SEC Filing
Form 4/A ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke
June 30, 2026 4:02 PM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jun 26 Filed by: Filius Bart
June 30, 2026 4:01 PM - SEC Filing
Form 6-K ProQR Therapeutics N.V. For: Jun 26
June 26, 2026 6:03 AM - SEC Filing
Form 424B5 ProQR Therapeutics N.V.
June 26, 2026 6:03 AM - SEC Filing
ProQR prices $50M share offering with Eli Lilly joining as buyer
June 25, 2026 6:35 AM - StreetInsider
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
June 25, 2026 6:35 AM - StreetInsider
Form 6-K ProQR Therapeutics N.V. For: Jun 25
June 25, 2026 6:31 AM - SEC Filing
ProQR reports positive Phase 1 data for RNA editing drug AX-0810
June 25, 2026 6:25 AM - StreetInsider
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
June 25, 2026 6:25 AM - StreetInsider
Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.
June 3, 2026 5:25 PM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke
June 3, 2026 4:01 PM - SEC Filing
Form 6-K ProQR Therapeutics N.V. For: Jun 02
June 2, 2026 4:02 PM - SEC Filing
Form 3 ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke
June 2, 2026 4:02 PM - SEC Filing
ProQR Therapeutics N.V. (PRQR) Reiterated at Market Outperform by Citizens
May 27, 2026 5:52 AM - StreetInsider
Form 6-K ProQR Therapeutics N.V. For: Mar 31
May 12, 2026 7:01 AM - SEC Filing
ProQR Announces First Quarter 2026 Operating and Financial Results
May 12, 2026 7:00 AM - Globe NewsWire
Form 6-K ProQR Therapeutics N.V. For: May 12
May 12, 2026 7:00 AM - SEC Filing
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
May 11, 2026 8:00 AM - Globe NewsWire
Form 6-K ProQR Therapeutics N.V. For: May 04
May 4, 2026 8:06 AM - SEC Filing
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
May 4, 2026 8:00 AM - StreetInsider
Form 6-K ProQR Therapeutics N.V. For: Apr 30
April 30, 2026 8:13 AM - SEC Filing
ProQR nominates Boehringer Ingelheim executive to board of directors
April 30, 2026 8:01 AM - StreetInsider
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
April 30, 2026 8:00 AM - Globe NewsWire
Full Article List
